Fiscal Year: January - December
DexCom, Inc. (DXCM), listed on the NASDAQ, has a market capitalization of $27.96B. As of Jun 20, 2026, the stock is trading at $72.47 per share@else an unavailable price , offering investors a clear view of its current market value. DexCom, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 30.99, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. DexCom, Inc. also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that DexCom, Inc. (DXCM) may be overvalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for DexCom, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for DexCom, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for DexCom, Inc. is 19.56, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, DexCom, Inc. (DXCM) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether DexCom, Inc. (DXCM) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be overvalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of DexCom, Inc. (DXCM) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of DexCom, Inc.. To access the full SS Score, consider upgrading your subscription.
DexCom, Inc. is a significant player in the industry sector, with a market capitalization of $27.96B and a competitive P/E ratio of 30.99. Investors should compare these metrics with industry peers to gauge whether DexCom, Inc. is outperforming or underperforming within its sector.
TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.
Piper Sandler analyst Matt O’Brien raised the firm’s price target on DexCom (DXCM) to $88 from $75 and keeps an Overweight rating on the shares. The firm is updating a…
The U.S. Food and Drug Administration said on Friday it has expanded the use of Dexcom's Stelo Glucose Biosensor System to children with diabetes, making it the first over-the-counter continuous glu...
The U.S. Food and Drug Administration cleared for marketing the first over-the-counter continuous glucose monitor for children, Dexcom (DXCM) Inc.’s Stelo Glucose Biosensor System, an integrated CGM i...
Drug wholesaler Pharmsource LLC said it was unaware the Dexcom glucose sensors it bought from licensed distributors had been slated for destruction, after the device maker warned some units were sto...
TD Cowen analyst Joshua Jennings raised the firm’s price target on DexCom (DXCM) to $95 from $75 and keeps a Buy rating on the shares. The firm said the company…
Mizuho raised the firm’s price target on DexCom (DXCM) to $85 from $75 and keeps an Outperform rating on the shares after attending the American Diabetes Association meeting. DexCom’s randomized…
Raymond James raised the firm’s price target on DexCom (DXCM) to $91 from $81 and keeps a Strong Buy rating on the shares. While acknowledging the high expectations, the CONNECT…
DexCom (DXCM) announced results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in g...
Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not using insulin, compared with routine care, acc...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically si...
Stifel analyst Jonathan Block raised the firm’s price target on DexCom (DXCM) to $90 from $85 and keeps a Buy rating on the shares. The firm’s survey of 35 doctors,…
DexCom (DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of diabetes and usherin...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for peop...
SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc., the global leader in glucose biosensing, today released its inaugural Customer Advisory Council Report, detailing candid feedback from users, caregivers, heal...
Citi raised the firm’s price target on DexCom (DXCM) to $84 from $79 and keeps a Buy rating on the shares. The firm updated models in the medical technology space…
Health tech startup Signos announced a $20 million funding round and expanded its partnership with medical device giant Dexcom. Signos makes an AI-powered glucose monitoring system designed to help wi...
DexCom (DXCM) announced through ongoing quality and accounting reviews it recently identified certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen ...
Medical device maker Dexcom said on Tuesday some of its glucose sensors slated for destruction were instead stolen and sold, prompting the company to warn users not to use products from two affected...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in glucose biosensing, announced today through ongoing quality and accounting reviews it recently identified certain lots of ...
DexCom (DXCM) announced Dexcom Flex, a new CGM system designed specifically for adults with Type 2 diabetes who are not using intensive insulin therapy. The new system will be available…
SAN DIEGO & EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in continuous glucose monitoring, today announced Dexcom Flex, a new CGM system designed specifically for...
BofA analyst Travis Steed lowered the firm’s price target on DexCom (DXCM) to $80 from $100 and keeps a Buy rating on the shares following the company’s analyst day and…
Canaccord lowered the firm’s price target on DexCom (DXCM) to $82 from $100 and keeps a Buy rating on the shares. The firm atteended its Investor Day where management outlined…
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2026 | 993.48M | Analyst x6 | |
| 2027 | 1,242.73M | 25.09% | Analyst x6 |
| 2028 | 1,516.53M | 22.03% | Analyst x6 |
| 2029 | 1,736.03M | 14.47% | Analyst x4 |
| 2030 | 1,940.23M | 11.76% | Analyst x3 |
| 2031 | 2,059.85M | 6.17% | Est @6.2% |
| 2032 | 2,165.21M | 5.12% | Est @5.1% |
| 2033 | 2,259.88M | 4.37% | Est @4.4% |
| 2034 | 2,341.35M | 3.60% | Est @3.6% |
| 2035 | 2,417.73M | 3.26% | Est @3.3% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 630.70M | 1.00 | 630.70M |
| 2025A | 1.08B | 1.00 | 1.08B |
| 2026E | 993.48M | 1.10 | 906.53M |
| 2027E | 1.24B | 1.20 | 1.03B |
| 2028E | 1.52B | 1.32 | 1.15B |
| 2029E | 1.74B | 1.44 | 1.20B |
| 2030E | 1.94B | 1.58 | 1.23B |
| 2031E | 2.06B | 1.73 | 1.19B |
| 2032E | 2.17B | 1.90 | 1.14B |
| 2033E | 2.26B | 2.08 | 1.09B |
| 2034E | 2.34B | 2.28 | 1.03B |
| 2035E | 2.42B | 2.50 | 967.40M |
| Terminal | 34.94B | 2.50 | 13.98B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.
